• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals Inc (NQ: ABOS )

    2.845 -0.035 (-1.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 104,417
    Open 2.890
    Bid (Size) 2.750 (11)
    Ask (Size) 3.000 (3)
    Prev. Close 2.880
    Today's Range 2.790 - 2.940
    52wk Range 1.810 - 5.090
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -32.74%
    -32.74%
    1 Month
    +13.80%
    +13.80%
    3 Month
    -4.85%
    -4.85%
    6 Month
    -18.48%
    -18.48%
    1 Year
    +45.15%
    +45.15%

    More News

    Read More
    Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024
    Via InvestorPlace
    Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Trading SMID Biotech Stocks In A Volatile Market
    Via Talk Markets
    ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
    Via InvestorPlace
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 26, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.